Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.

Aaronson D, Cowan J, Carroll P, Konety B.

BJU Int. 2010 Apr;105(7):951-5. doi: 10.1111/j.1464-410X.2009.08886.x. Epub 2009 Nov 4.

2.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

4.

Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.

Song C, Kim YS, Hong JH, Kim CS, Ahn H.

BJU Int. 2010 Jul;106(2):188-93. doi: 10.1111/j.1464-410X.2009.09136.x. Epub 2009 Dec 11.

5.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
6.

Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.

Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):36-9. doi: 10.1016/j.ijrobp.2008.10.059. Epub 2009 Feb 23.

PMID:
19233568
7.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62. Epub 2005 Sep 19.

PMID:
16169682
8.

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.

BJU Int. 2009 Nov;104(9):1208-14. doi: 10.1111/j.1464-410X.2009.08593.x. Epub 2009 Apr 17.

9.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
10.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
11.

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.

Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.

Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304.

12.
13.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
14.

Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.

Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB.

Cancer. 2009 Apr 15;115(8):1784-90. doi: 10.1002/cncr.24176.

16.

Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.

Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1302-8. doi: 10.1016/j.ijrobp.2007.11.073. Epub 2008 Feb 11.

PMID:
18262732
17.

Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.

Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.

Cancer. 2009 Oct 1;115(19):4470-6. doi: 10.1002/cncr.24526.

18.

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52. doi: 10.1016/j.ijrobp.2009.06.038. Epub 2009 Oct 26.

PMID:
19864082
19.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

PMID:
19858385
20.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55.

PMID:
15001244

Supplemental Content

Support Center